Johnson & Johnson (NYSE:JNJ) went up by 0.36% from its latest closing price compared to the recent 1-year high of $157.00. The company’s stock price has collected 1.11% of gains in the last five trading sessions. MarketWatch Automation reported 23 hours ago that Dow jumps 175 points on gains for shares of Apple Inc., Dow Inc.
Is It Worth Investing in Johnson & Johnson (NYSE :JNJ) Right Now?
Johnson & Johnson (NYSE:JNJ) scored a price-to-earnings ratio above its average ratio, recording 26.71 x from its present earnings ratio. Plus, the 36-month beta value for JNJ is at 0.69. Opinions of the stock are interesting as 10 analysts out of 17 who provided ratings for Johnson & Johnson declared the stock was a “buy,” while 2 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $164.87, which is $16.17 above the current price. JNJ currently public float of 2.63B and currently shorts hold a 0.40% ratio of that float. Today, the average trading volume of JNJ was 6.22M shares.
JNJ’s Market Performance
JNJ stocks went up by 1.11% for the week, with a monthly jump of 0.44% and a quarterly performance of 3.07%, while its annual performance rate touched 14.94%. The volatility ratio for the week stands at 1.58% while the volatility levels for the past 30 days are set at 1.86% for Johnson & Johnson. The simple moving average for the period of the last 20 days is -1.19% for JNJ stocks with a simple moving average of 2.84% for the last 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with UBS repeating the rating for JNJ by listing it as a “Neutral.” The predicted price for JNJ in the upcoming period, according to UBS is $160 based on the research report published on April 28th of the current year 2020.
BofA/Merrill, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $175, previously predicting the value of $150. The rating they have provided for JNJ stocks is “Buy” according to the report published on April 22nd, 2020.
Citigroup gave a rating of “Buy” to JNJ, setting the target price at $163 in the report published on March 5th of the current year.
JNJ Trading at 0.22% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.17% of loss for the given period.
Volatility was left at 1.86%, however, over the last 30 days, the volatility rate increased by 1.58%, as shares sank -0.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.13% upper at present.
During the last 5 trading sessions, JNJ rose by +1.11%, which changed the moving average for the period of 200-days by +8.09% in comparison to the 20-day moving average, which settled at $150.68. In addition, Johnson & Johnson saw 2.07% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at JNJ starting from Wengel Kathryn E, who sold 16,115 shares at the price of $153.52 back on Sep 02. After this action, Wengel Kathryn E now owns 58,420 shares of Johnson & Johnson, valued at $2,473,938 using the latest closing price.
McEvoy Ashley, the EVP, WW Chair, Medical Devices of Johnson & Johnson, sold 29,000 shares at $147.47 during a trade that took place back on Jul 28, which means that McEvoy Ashley is holding 21,682 shares at $4,276,630 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- +26.24 for the present operating margin
- +66.95 for the gross margin
The net margin for Johnson & Johnson stands at +18.41. The total capital return value is set at 24.16, while invested capital returns managed to touch 17.37. Equity return is now at value 25.10, with 9.70 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 48.23 points at debt to equity in total, while total debt to capital is 32.54. Total debt to assets is 18.18, with long-term debt to equity ratio resting at 25.69. Finally, the long-term debt to capital ratio is 45.75.
When we switch over and look at the enterprise to sales, we see a ratio of 4.88, with the company’s debt to enterprise value settled at 0.07. The receivables turnover for the company is 5.75 and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.